Table 2.
Ublituximab activity by dose cohort (Phase 1)
| Dose (mg) | Disease | DLT | Best response |
|---|---|---|---|
| 450 | MZL | No | CR |
| FL | No | PD | |
| MCL | No | PD | |
| 600 | FL | No | SD |
| FL | No | SD | |
| MZL | No | CR | |
| CLL | No | NE | |
| CLL | No | NE | |
| CLL | No | PR | |
| CLL | No | PR | |
| CLL | No | PR | |
| 900 | FL | No | CR |
| FL | No | CR | |
| MZL | No | PR | |
| CLL | No | SD | |
| CLL | No | SD | |
| CLL | No | SD | |
| 1200 | FL | No | SD |
| FL | No | PD | |
| MCL | No | SD |
CLL, chronic lymphocytic leukaemia; CR, complete response; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NE, not evaluable; PD, progressive disease; PR, partial response, SD, stable disease.
Note: Non‐evaluable patients discontinued study prior to first disease assessment (one patient with pneumonia deemed unrelated to study, and one patient withdrew consent).